The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Baker, Amanj and Chen, Li-Chia and Elliott, Rachel A. and Godman, Brian (2015) The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. BMC Health Services Research, 15. 367. ISSN 1472-6963

[img]
Preview
Text (Baker-etal-BMCHSR-2015-The-impact-of-the-better-care-better-value-prescribing-policy-on-the-utilisation-of-angiotensin-converting-enzyme-inhibitors)
Baker_etal_BMCHSR_2015_The_impact_of_the_better_care_better_value_prescribing_policy_on_the_utilisation_of_angiotensin_converting_enzyme_inhibitors.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (660kB)| Preview

    Abstract

    In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.